Prostatic arterial embolization (PAE) is safe and effective for treating benign prostatic hyperplasia (BPH) in men with medium and large prostates, according to the findings of a Chinese study published online in BJU International.
The study, by Maoqiang Wang, MD, and colleagues, included 115 men with a mean age of 71.5 years diagnosed with lower urinary tract symptoms due to BPH refractory to medical treatment. Researchers divided the patients into 2 groups: Group A included patients with large prostates (mean volume of 129 mL) and group B included patients with a medium-size prostate (mean volume of 64 mL).
Results showed no significant difference in technical success rate between groups A and B (93.8% and 96.8%). Of the 115 men, 101 (55 in group A and 46 in group B) completed follow-up (mean 17 months). After PAE, both groups experienced significant improvements from baseline in International Prostate Symptom Score (IPSS), quality of life (QoL), post-void residual (PVR), prostate volume (PV), and maximum flow rate (Qmax). Outcomes in group A were significantly better with respect to IPSS, Qmax, PVR, PV, and QoL compared with group B.